China · Delayed Price · Currency is CNY Bright Eye Hospital Group Statistics
Total Valuation
SHE:301239 has a market cap or net worth of CNY 4.99 billion. The enterprise value is 6.50 billion.
| Market Cap | 4.99B |
| Enterprise Value | 6.50B |
Important Dates
The next estimated earnings date is Tuesday, April 28, 2026.
| Earnings Date | Apr 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SHE:301239 has 148.86 million shares outstanding. The number of shares has increased by 5.37% in one year.
| Current Share Class | 148.86M |
| Shares Outstanding | 148.86M |
| Shares Change (YoY) | +5.37% |
| Shares Change (QoQ) | +1.23% |
| Owned by Insiders (%) | 44.09% |
| Owned by Institutions (%) | 17.47% |
| Float | 70.04M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.82 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 3.01 |
| P/FCF Ratio | 31.38 |
| P/OCF Ratio | 13.07 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.15, with an EV/FCF ratio of 40.84.
| EV / Earnings | -64.10 |
| EV / Sales | 2.37 |
| EV / EBITDA | 15.15 |
| EV / EBIT | 67.80 |
| EV / FCF | 40.84 |
Financial Position
The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.90.
| Current Ratio | 1.07 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.90 |
| Debt / EBITDA | 4.51 |
| Debt / FCF | 12.15 |
| Interest Coverage | 1.10 |
Financial Efficiency
Return on equity (ROE) is -4.28% and return on invested capital (ROIC) is 2.66%.
| Return on Equity (ROE) | -4.28% |
| Return on Assets (ROA) | 1.29% |
| Return on Invested Capital (ROIC) | 2.66% |
| Return on Capital Employed (ROCE) | 2.53% |
| Revenue Per Employee | 535,467 |
| Profits Per Employee | -19,792 |
| Employee Count | 5,121 |
| Asset Turnover | 0.59 |
| Inventory Turnover | 9.46 |
Taxes
In the past 12 months, SHE:301239 has paid 74.21 million in taxes.
| Income Tax | 74.21M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.43% in the last 52 weeks. The beta is 0.74, so SHE:301239's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -18.43% |
| 50-Day Moving Average | 33.46 |
| 200-Day Moving Average | 38.36 |
| Relative Strength Index (RSI) | 64.34 |
| Average Volume (20 Days) | 1,855,434 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SHE:301239 had revenue of CNY 2.74 billion and -101.35 million in losses. Loss per share was -0.66.
| Revenue | 2.74B |
| Gross Profit | 1.09B |
| Operating Income | 95.84M |
| Pretax Income | -19.87M |
| Net Income | -101.35M |
| EBITDA | 237.34M |
| EBIT | 95.84M |
| Loss Per Share | -0.66 |
Balance Sheet
The company has 446.45 million in cash and 1.93 billion in debt, with a net cash position of -1.49 billion or -9.99 per share.
| Cash & Cash Equivalents | 446.45M |
| Total Debt | 1.93B |
| Net Cash | -1.49B |
| Net Cash Per Share | -9.99 |
| Equity (Book Value) | 2.14B |
| Book Value Per Share | 14.27 |
| Working Capital | 60.31M |
Cash Flow
In the last 12 months, operating cash flow was 382.08 million and capital expenditures -222.98 million, giving a free cash flow of 159.10 million.
| Operating Cash Flow | 382.08M |
| Capital Expenditures | -222.98M |
| Free Cash Flow | 159.10M |
| FCF Per Share | 1.07 |
Margins
Gross margin is 39.74%, with operating and profit margins of 3.49% and -3.70%.
| Gross Margin | 39.74% |
| Operating Margin | 3.49% |
| Pretax Margin | -0.72% |
| Profit Margin | -3.70% |
| EBITDA Margin | 8.66% |
| EBIT Margin | 3.49% |
| FCF Margin | 5.80% |
Dividends & Yields
SHE:301239 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.37% |
| Shareholder Yield | -5.37% |
| Earnings Yield | -2.03% |
| FCF Yield | 3.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SHE:301239 has an Altman Z-Score of 2.35 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.35 |
| Piotroski F-Score | 4 |